Hypertension Management with Labetalol

Introduction to Labetalol

Labetalol begins to lower blood pressure within 5-10 minutes, with peak effects occurring within 5-15 minutes after administration and a duration of action of 3-6 hours, according to the European Heart Journal 1
The onset of action is 5-10 minutes, the peak effect is 5-15 minutes after administration, and the duration of action is 3-6 hours, as reported by the European Heart Journal 1

In cases of acute aortic dissection, labetalol (along with esmolol) is the preferred agent for rapid lowering of systolic BP to ≤120 mm Hg within 20 minutes, as recommended by the American Heart Association and the American College of Cardiology 2, 3
For acute coronary syndromes, labetalol is one of the preferred agents, but it is contraindicated in moderate-to-severe LV failure with pulmonary edema, bradycardia, hypotension, poor peripheral perfusion, second/third-degree heart block, and reactive airways disease, according to the American Heart Association and the American College of Cardiology 2, 3
In eclampsia or preeclampsia, labetalol is a first-line agent (along with hydralazine and nicardipine) and requires rapid BP lowering, with an initial dose of 0.25-0.5 mg/kg IV bolus; 2-4 mg/min continuous infusion until goal BP is reached, as recommended by the European Heart Journal and the American College of Cardiology 1, 2, 3

For patients eligible for thrombolytic therapy with systolic BP >185 mmHg or diastolic BP >110 mmHg, labetalol 10-20 mg IV over 1-2 minutes may be given, and repeated once if necessary, as recommended by the American Heart Association and the American Stroke Association 4, 5, 6
If BP is not reduced and maintained below 185/110 mmHg, thrombolytic therapy should not be administered, according to the American Heart Association and the American Stroke Association 6

Absolute contraindications for labetalol include second or third-degree AV block, reactive airways disease/asthma, and decompensated heart failure, as stated by the American Heart Association and the European Heart Journal 1, 2
Monitoring is needed as labetalol may worsen heart failure and should not be given in patients with bradycardia, according to the American Heart Association 2
Lower dosing adjustment is required for elderly patients, as recommended by the American Heart Association 2